Genialis
Genialis is a precision oncology company that leverages advanced AI and deep biological expertise to develop clinically actionable RNA biomarkers and therapeutic intelligence solutions. Their…
Genialis
Genialis is a precision oncology company that leverages advanced AI and deep biological expertise to develop clinically actionable RNA biomarkers and therapeutic intelligence solutions. Their…
TL;DR
Sector: Precision oncology / Biotechnology
Founded: 2015
Core product: AI/ML-driven RNA biomarker discovery platforms (Genialis Supermodel, ResponderID, krasID)
Business model: SaaS and services for pharma and diagnostics partners
Recent financing: Series A (announced Mar 29, 2023) raising >$13M
Company Overview
Problem Domain
Precision oncology biomarker discovery and patient-response prediction for clinical trials and drug development.
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
2300000
Seed round co-led by Redalpine and First Star Ventures with participation from Pikas and angels.
13000000
Series A announced co-led by Taiwania Capital and Debiopharm Innovation Fund (reported as more than $13M).
Investor Signal
“Debiopharm Innovation Fund and Taiwania Capital Management Corporation are lead/co-lead investors; participation from Redalpine, First Star Ventures, Pikas, and P5 Health Ventures.”
